Kaiser Health News

OCTOBER 7, 2024

senators have pressed the FDA to take steps to eliminate pulse oximetry’s racial bias, which has caused delays in treatment and worse health outcomes, and more recently has raised concern about the reliability of hospital AI tools that draw on reams of data from the devices. . The FDA’s response was modest.

FDA 129

FDA Doctors Hospitals Health Outcomes 129

Health Populi

MAY 30, 2018

Data provided to the FDA from patients who have used the product demonstrate a variety of side effects including but not limited to nausea, headache, slowed breathing, and amnesia — but not racism as far as the post-marketing surveillance has revealed. .”

FDA 89

FDA Health Outcomes Public Health 89

SQA

AUGUST 8, 2023

TR 43 was originally published in 2007 and revised in 2013 to address industry feedback. Although this Toolkit provides PCPCs current thinking on MoCRA, companies should be mindful that MoCRA represents meaningful new authorities that FDA has yet to interpret and apply. TR 43 applies solely to empty glass containers.

FDA 40

FDA Compliance COVID-19 World Health 40

SQA

AUGUST 8, 2023

TR 43 was originally published in 2007 and revised in 2013 to address industry feedback. Although this Toolkit provides PCPC’s current thinking on MoCRA, companies should be mindful that MoCRA represents meaningful new authorities that FDA has yet to interpret and apply. TR 43 applies solely to empty glass containers.

FDA 40

FDA Compliance COVID-19 World Health 40

Bill of Health

AUGUST 29, 2022

Hill, A n Analysis of Racial/Ethnic Disproportionality and Disparity at the National, State, and County Levels , Casey-CSSP Alliance for Racial Equity in Child Welfare 1, 1 (2007), [link]. [3] Health Care Issues for Children and Adolescents in Foster Care and Kinship Care , 136 Pediatrics e1131, e1132 (2015). [6]

COVID-19 Vaccine 130

COVID-19 Vaccine COVID-19 Informed Consent Governance 130

Bill of Health

NOVEMBER 25, 2024

Food and Drug Administration (FDA). The FDA maintains that low levels of BPA exposure are safe for humans. However, the FDA has recognized that low levels of exposure are not safe during infant development and no longer allows BPA-based baby bottles, sippy cups , or packaging for infant formula.

FDA 100

FDA Public Health 100